New Four-Strain Flu Vaccine Covers Even the Youngest Patients

Sanofi Pasteur, the vaccines division of Sanofi, announced that the FDA has approved the supplemental biologics license application (sBLA) of Fluzone Quadrivalent vaccine, an inactivated four-strain influenza virus vaccine for intramuscular injection.

Fluzone Quadrivalent is the first four-strain vaccine approved for use in patients as young as 6 months. The vaccine includes two A strains and two B strains to help protect against influenza and is preservative-free. Fluzone Quadrivalent is the latest addition to the Fluzone family of vaccines that include Fluzone, Fluzone Intradermal, and Fluzone High-Dose–all of which are trivalent vaccines.

The Fluzone Quadrivalent vaccine will be available for the 2013–2014 influenza season. It will be supplied as 0.25mL and 0.5mL prefilled syringes in 10-count packages and 0.5mL single-dose vials in 10-count packages. Healthcare providers may reserve vaccines by visiting

For more information call (800) VACCINE or visit